

Timiskaming Health Unit Final Report of an Institutional Respiratory Infection Outbreak

Please **FAX** this final report to your respective Timiskaming Health Unit office within **1 week** of the outbreak being declared over. See instructions for assistance in completing this form.

THU <u>Confidential Fax Number</u>: **705-648-6305**

SECTION A: General Outbreak Information								
A-1	Institution Name:	iPHIS Outb			oreak #:			
			•					
A-2	Date of Onset	Resident/Patient Case		Staff Case				
	Illness in the first case (yy/mm/dd)							
	Illness in the last case (yy/mm/dd)							
					□ No Staff Cases			
A-3	Date Outbreak Declared Over (yy/mm/dd)							
	T							
A-4	Was the causative organism of the outbrea		onfirmed	?	□ Yes □ No			
	If lab-confirmed (A-4 is "yes"), check all that a	apply.	,					
	☐ Influenza A (subtype if available)		□ Influe	enza B (<i>subt</i>)	type if available)			
	□ RSV		□ Rhino	ovirus				
	□ Parainfluenza (<i>type if available</i>)		□ Adend	ovirus				
	☐ Enterovirus (specify if available)	□ Other (specify)						
A-5						□ Yes	□ No	
A-5a If "yes", specify the # of residents/patients immunized during this outbreak.								
	Hall factor Barret				1			
Initiate	List Infection Prevent					- N-		
Initiate additional precautions, isolation, & apply appropriate signage (i.e. droplet) upon identification of symptomatic resident/patient					□ Yes	□ No		
Maintain additional precautions for 5 days from symptom onset					□ Yes	□ No		
Utilize additional precautions: droplet personal protective equipment (gloves,				oves,	□ Yes	□ No		
gown, mask, and eye protection)								
Outbreak notification signage on facility door and ward					□ Yes	□ No		
Routine precautions (i.e. hand hygiene)					□ Yes	□ No		
Environmental controls (i.e. effective cleaning supplies against causative agent,			agent,	□ Yes	□ No			
increased cleaning)								
Notify Public Health upon 2 symptomatic resident/patients within a 48 hour			our	□ Yes	□ No			
period and declare outbreak? Public notice					□ Yes	□ No		
Facility closure to public					□ Yes	□ No		
Co-horting staff and resident/patient care					□ Yes	□ No		
Co-horting symptomatic residents (if in ward like setting)				□ Yes	□ No	□ N/A		
	tee norting symptomatic residence (ii iii ward into Setting)							

COMPLETE THIS SECTION FOR NON-INFLUENZA OUTBREAKS ONLY (i.e. outbreaks due to unknown organisms or organisms other than influenza) **SECTION B: Resident/Patient and Staff Information** Summary of Line Listed Cases♦ During Current Non-Influenza Outbreak B-1 Resident/Patient Staff Total # Cases◆ # Cases◆ admitted to hospital Cases ◆ with pneumonia (CXR+) # Deaths among cases • **B-2** Were antivirals used during this outbreak? □ Yes □ No If "yes" Provide reason for antiviral medication use during non-influenza outbreak: If "no" and this was a Non-Influenza outbreak, the Final Report is complete. For all other outbreaks, continue with sections C through F.

NOTE: ANTIVIRAL MEDICATION USE IS ONLY RECOMMENDED DURING LAB CONFIRMED INFLUENZA OUTBREAKS

COMPLETE **SECTIONS C TO F** FOR OUTBREAKS DUE TO **INFLUENZA OR COMBINED ONLY***

SECTION C: Current Influenza and Respiratory Infection Season Vaccination Status									
C-1	Current Influenza Vaccination Status								
		Total # Residents/Patients	# Residents/Patients Vaccinated Prior to Outbreak•	Total # Staff■	# Staff■Vaccinated Prior to Outbreak●				
	Entire Facility								
	Affected Area/Unit								

SECTION D: Resident/Patient and Staff Information							
D-1	Summary of Line Listed Residents/Patients During Current Influenza Outbreak						
	Information Related to the Current	Total #	# Resident/Patient	# Resident/Patient			
	Outbreak	Resident/Patien	Cases Vaccinated	Cases Not Vaccinated			
		t Cases	Prior to Outbreak•	Prior to Outbreak•			
	Total # Cases◆						
	# Cases◆ admitted to hospital						
	# Cases♦ with pneumonia (CXR+)						
	# Deaths among cases◆						
D-2	Summary of Line Listed Staff During Current Influenza Outbreak						
	Information Related to the Current	Total # Staff■	# Staff■ Cases	# Staff■ Cases Not			
	Outbreak	Cases	Vaccinated Prior to	Vaccinated Prior to			
			Outbreak•	Outbreak•			
	Total # Cases◆						
	# Cases◆ admitted to hospital						
	# Cases♦ with pneumonia (CXR+)						
	# Deaths among cases◆						

SECTION E: ■ Immunization						
E-1	Was influenza immunization offered to staff on-site this influenza season		□ No			
	(October-April)?					
E-2	Does the facility have a staff exclusion policy requiring staff influenza	□ Yes	□ No			
	immunization?					
E-3	Was influenza immunization offered to staff & residents on-site during the	□ Yes	□ No			
	current outbreak?					
E-3a	If "yes," specify the number of staff immunized during the current outbreak.					
E-4	Were staff excluded from work during the outbreak (because they were not	□ Yes	□ No			
	immunized and not on antiviral medication)?					
E-4a	If "yes," specify the number of staff excluded.					
E-5	Were staff excluded under policy of the facility?	□ Yes	□ No			
E-6	Were staff excluded by Medical Officer of Health (MOH) (by order under section	□ Yes	□ No			
	22 of the Health Protection and Promotion Act?)					

	COMPLETE THIS SECTION <u>ONL</u> SECTIO	<u>.Y</u> IF ANTIVIRALS IN F: Antiviral M o			NG THE OUTBRE	AK			
F-1	Was antiviral prophylaxis initiated within 24 hours of a laboratory confirmed ☐ Yes ☐ No influenza outbreak?							٧o	
	Was antiviral medication administe	ered to residents,	/patients?		□ Y	'es	□ 1	No	
F-2	Was antiviral medication administe	ered to staff?			_ Y	'es	_ l	Vo	
F-2a	If "yes", please specify under what circumstances, i.e. were they vaccinated or not?								
F-3	Summary of Residents/Patients and Staff who Received Antiviral Medication								
		Residents/Patie	nts	# S	taff				
	Those not yet ill (prophylaxis)								
	III persons within 48 hours of onset	of symptoms (tr	eatment)						
	Ill persons > 48 hours after onset of symptoms (NOT								
	recommended)								
F-4	Summary of the Length of	Antiviral Medica	ition Usage fo	or Re	sidents/Patient	s and	Staf	f	
		Residen	nts/Patients		9	Staff			
	Antiviral Used	Amantadine	Oseltami	vir	Amantadine		Oseltamivir		
			(Tamiflu)			(Tamiflu		flu)	
	Range \star (minimum to maximum								
	length of prophylaxis (in days))								
	Length of treatment (in days)								
F-5	Did amantadine/oseltamivir appear to decrease the number of new Yes No Uncertain						rtain		
	cases among residents/patients within 72 hours?								
F-5a		dditional nasopharyngeal specimens sent to the laboratory?				□Y	es	□ No	
F-6	1	Did anyone contract influenza-like-illness (ILI) while on antiviral prophylaxis for a					'es	□ No	
	minimum of 72 hours?								
F-6a	If "yes", how many people contracted ILI while on antiviral prophylaxis?								
F-6b	If "yes", were any of the cases lab-					□ Y	es	□ No	
		<u>er </u> F-7 to F-10 <u>ON</u>		<u>nivir</u> v					
F-7	How many people developed side 6	effects to oseltar	nivir?		# of residents/patients:				
						# of staff:			
F-8	If side effects to oseltamivir were reported, specify below (use 'other' for symptoms not listed).								
	□ headache □ fatigue □	nausea □ diarrhea □ cough				□ vomiting			
	□ abdominal □ insomnia □	vertigo 🗆 🖰	other <i>(specif</i> y	/)					
	pain (d	dizziness)							
F-9	Of those that developed side effects, how many discontinued use # of residents/patients:					nts:			
	of oseltamivir due to side effects?				# of staff:				